Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD.

Next Previous
Trial Profile

Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Vorinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms VBDD

Most Recent Events

  • 02 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database record.
  • 27 Jun 2014 Planned End Date changed from 1 Sep 2014 to 1 Mar 2017 reported by ClinicalTrials.gov.
  • 18 Jan 2012 German Clinical Trials Register reports actual initiation date as 20 Sep 2011.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top